Recent advances and significance of intra-arterial infusion chemotherapy in non-resectable colorectal liver metastasis

Journal of Gastrointestinal Oncology

Volumn 4, Issue 2, 2013, Pages 164-172

  Nanashima, Atsushi ^a   Takeshita, Hiroaki ^a   Abo, Takafumi ^a   Tou, Kazuo ^a   Tanaka, Kenji ^a   Fukuda, Daisuke ^a   Kunizaki, Masaki ^a   Hidaka, Shigekazu ^a   Sawai, Terumitsu ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Hepatic intraarterial infusion chemotherapy; Longer survival; Non resectable colorectal liver metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CATHETER COMPLICATION; CATHETER DISLOCATION; CATHETER INFECTION; CATHETER OCCLUSION; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; COLORECTAL TUMOR; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEPATIC ARTERY; HUMAN; LEUKOPENIA; LIVER METASTASIS; LIVER RESECTION; MALE; MEDICAL FEE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TUMOR GROWTH;

EID: 84995757526     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2013.005     Document Type: Article

References (37)

1. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989;210:127-38.
2. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Registry of Hepatic Metastases. Surgery 1988;103:278-88.
3. Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg 1995;19:59-71.
4. Figueras J, Torras J, Valls C, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum 2007;50:478-88.
5. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003;14:ii13-6.
6. Wicherts DA. Chapter 1. general outline and introduction of the thesis. In: Wicherts DA. eds. New strategies for advanced colorectal liver metastases. No more a fatality. Enschede, Netherlands: Gildeprint Drukkerijen. 2011:10-7.
7. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759-66.
8. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-25; discussion 825-7.
9. Folprecht G, Lutz MP, Schöffski P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006;17:450-6.
10. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
11. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052-61; discussion 1061-4.
12. Lopez P, Marzano E, Piardi T, et al. Repeat hepatectomy for liver metastases from colorectal primary cancer: a review of the literature. J Visc Surg 2012;149:e97-e103.
13. Sa Cunha A, Laurent C, Rault A, et al. A second liver resection due to recurrent colorectal liver metastases. Arch Surg 2007;142:1144-9; discussion 1150.
14. Yamamoto J, Kosuge T, Shimada K, et al. Repeat liver resection for recurrent colorectal liver metastases. Am J Surg 1999;178:275-81.
15. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-75.
16. Pohlen U, Mansmann U, Berger G, et al. Multicenter pilot study of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres via hepatic arterial infusion in patients with nonresectable colorectal liver metastases. Anticancer Res 2004;24:3275-82.
17. Boyle P, Leon ME. Epidemiology of colorectal cancer. Br Med Bull 2002;64:1-25.
18. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-6.
19. Köhne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23:4856-65.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
21. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47.
22. Gotlib V, Khaled S, Lapko I, et al. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 2006;17:1227-9.
23. Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19:734-8.
24. Stillwell AP, Ho YH, Veitch C. Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg 2011;35:684-92.
25. Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008;15:219-26.
26. Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005;23:4881-7.
27. Nanashima A, Tobinaga S, Abo T, et al. Reducing the incidence of post-hepatectomy hepatic complications by preoperatively applying parameters predictive of liver function. J Hepatobiliary Pancreat Sci 2010;17:871-8.
28. Japanese Society for Cancer of the Colon and Rectum. 3.2.2 In: Mutoh T. eds. General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus (in Japanese). 7th ed. Tokyo: Kanehara & Co., Ltd., 2006:14-5.
29. Allen PJ, Nissan A, Picon AI, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 2005;201:57-65.
30. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003;361:368-73.
31. Mocellin S, Pilati P, Lise M, et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007;25:5649-54.
32. Chan R, Kerr D. Hepatic arterial chemotherapy for colorectal cancer liver metastases: a review of advances in 2003. Curr Opin Oncol 2004;16:378-84.
33. Aparicio J, Fernandez-Martos C, Vincent JM, et al. FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 2005;5:263-7.
34. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24:1395-403.
35. Seki H, Ozaki T, Shiina M. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. Cardiovasc Intervent Radiol 2009;32:679-86.
36. Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005;23:4888-96.
37. Kanat O, Gewirtz A, Kemeny N. What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer. J Gastrointest Oncol 2012;3:130-8.